We could show that a combination of S63845 either with ATP-competitive TKIs or with asciminib, a highly selective, allosteric ABL1 kinase inhibitor [24] exerted similar synergistic proapoptotic effect on CML cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.